SETD2 and lung cancer: Consistent with these observations and previous lung cancer mouse modeling studies (22, 32, 33), we find that SETD2 ablation strongly accelerates LUAD malignant progression and lethality in a KRASG12C-driven mouse tumor model (see Fig. 1).